Amid slug­gish sales and du­el­ing law­suits, No­var­tis bows out of Am­gen part­ner­ship, slash­es staff

When No­var­tis and Am­gen got Aimovig ap­proved in 2018, most mi­graine pa­tients re­lied on decades-old, mild­ly ef­fec­tive pills to ease their headaches. Proven to re­duce mi­graines by more than 50% in hard-to-treat pa­tients, Aimovig was ex­pect­ed to quick­ly rake in over $1 bil­lion per year.

In the three years since, though, a slew of ri­vals have en­tered: near­ly iden­ti­cal treat­ments from Eli Lil­ly, Al­ler­gan, and Te­va, along­side new oral op­tions from Bio­haven. Now, with com­pe­ti­tion tight­en­ing and re­la­tions be­tween the two tense, No­var­tis is pulling out of the US mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.